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See related article on page 486. Sentinel node mapping techniques have been applied to the resectionand treatment of nearly all solid tumors. The principle involves theinjection of a lymphophylic tracer (either blue dye or a radioisotope)followed by visual or gamma counter measurements of individuallymph node stations to assess the first site of lymphatic drainage froma tumor. This sentinel nodal station should be the first site of lym-
phatic involvement if metastases have occurred.
The technique has become standard of care in both breast cancer and melanoma.
The primary utility in these tumors is avoidance of nontherapeutic axillary or groin
lymph node dissections and their incumbent morbidities. The morbidity of a
complete mediastinal node dissection for lung cancer is not excessive and the
procedure may be therapeutic.1,2
An equally important potential role may be directing pathologic examination to
specific sentinel nodes and applying more sensitive techniques on a limited amount
of tissue to detect occult micrometastatic disease.
Lymph node status is the single most important prognostic factor for localized
potentially resectable non–small cell lung cancer.3 Recent studies suggest that the
presence of nodal micrometastatic disease in lung cancer may garner the same poor
prognosis as metastases evident by conventional techniques.4,5 Nonetheless, more
than 40% of “histologically node negative” patients who have a complete resection
have a relapse and die of their original cancers, usually within 2 years. This is at
least in part due to inaccurately staged nodal disease.
Sentinel node mapping in lung cancer is in the developmental phase. Numerous
questions regarding technique, patient selection, and ultimate utility still remain unan-
swered. Initial studies by our group and others6-8 have demonstrated the feasibility of
intraoperative injection of both blue dye and radioisotope for sentinel node mapping.
The report by Nomori and colleagues9 in this issue of the Journal examines the
sentinel node procedure by preoperative tumor injection with technetium Tc 99m tin
colloid. The larger technetium tin colloid molecule required at least 6 hours to
migrate to a sentinel node station as demonstrated by lymphoscintigraphy. This is
compared to 10 to 15 minutes with the 20-m filtered smaller technetium 99m
sulfur colloid particle used in our intraoperative studies. The larger particle appears
better suited for the preoperative injection performed the day before surgery.
The current study details results in 46 patients after injection 1 day preoperatively
with technetium tin colloid. Nomori and associates obtained accurate sentinel node
readings in 40 of the 46 patients undergoing anatomic resection with mediastinal
node dissection for NSCLC. No inaccurate sentinel nodes were found in the 14
patients with N1 or N2 disease.
Technical Factors and Selection Criteria
We have now performed the intraoperative mapping procedure in more than 150
patients. We have noted less success of the technique in patients with large necrotic
tumors as well as those with hilar and mediastinal adenopathy. The reasons for this
are intuitive. Larger necrotic tumors may have altered lymphatic and vascular
supply and established adenopathy may cause efferent lymphatic obstruction.
Clearly, the technique holds the most promise in patients with small clinically early
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stage tumors. Those patients with adenopathy and bulky
tumors will more than likely have multiple involved nodal
stations.
Nomori and colleagues9 also noted that patients with
chronic obstructive pulmonary disease were less likely to
have identifiable sentinel nodes with their technique. One
possible explanation would be an attenuation of lymphatics
along with the loss of alveoli and functional lung tissue seen
with emphysema. Further study will elucidate whether these
patterns continue.
Intraoperative Versus Preoperative Technique
In Japan the use of radioisotopes is strictly limited to des-
ignated areas. The intraoperative injection technique is im-
practical in this environment. The benefits of preoperative
tumor injection the night before include better logistical
coordination with nuclear medicine and radiation safety
issues and the ability to perform preoperative imaging to
plan surgery. These are balanced by the patient requiring a
separate procedure with the small but real risks of pneumo-
thorax, bleeding, and tumor seeding of the needle tract.
Which technique will ultimately be used is unclear, as
currently available data show both to have reasonable sen-
tinel node detection rates.
“Skip Metastases”
Mediastinal lymph node involvement without concurrent
spread to the intraparenchymal and hilar nodal basins has
been termed “skip metastasis,” The incidence of this phe-
nomenon in patients with positive N2 mediastinal nodes has
been reported to be between 20% to 30% in most series.10
Recent studies have attempted to distinguish between pa-
tients with skip N2 metastases and those with traditional N1
and N2 positive findings by arguing that patients with the
skip pattern have a prognosis similar to that of patients with
stage II (N1) rather than stage III (N2) disease.11 New data
suggest that the nearly 40,000 patients with stage III locore-
gionally advanced disease have a wide variation of prog-
noses within the same stage.11 The sentinel node technique
may allow better understanding of common drainage pat-
terns of different tumor locations. This may lead to im-
proved prognostic separation of patients based on the num-
ber and degree (gross/micrometastatic) of nodes involved.
The impact on overall prognosis, therapeutic decision-mak-
ing, and new staging systems remains to be determined.
Nomori and colleagues9 reported 14 of 40 sentinel nodes
as mediastinal. Their ability to identify these in vivo was
highly accurate (88%). Although the sentinel node tech-
nique may not ever be used to stratify those requiring a full
mediastinal node dissection from a sampling or no dissec-
tion, the information gained from detailing the actual nodal
drainage of each tumor will continue to blur the lines
between N1 and N2 disease, calling for a reconsideration of
the staging of single site skip pattern metastases.
Micrometastases/Ultrastaging
Nomori’s group9 found no micrometastases in the 26 sen-
tinel nodes classified as negative by standard histologic
evaluation. The authors report performing additional 3-step
sections and immunohistochemistry with cytokeratin anti-
bodies. This is in contrast to our recent report7 detailing
results in our first 100 patients in which 7 patients were
upstaged with the identification of micrometastatic disease
in the sentinel nodes. We performed serial sections at
30-m intervals (average 10 per slide) as well as cytoker-
atin antibody staining.
With the increasing availability of real time reverse tran-
scriptase–polymerase chain reaction analysis and other even
more sensitive techniques to identify single cell nodal me-
tastases, the future role of sentinel node identification in
directing these examinations to the most likely site for
metastases remains promising. Likewise molecular staging
techniques may become more prognostically important as
more specific markers and patterns are identified.12 The
partnering of more precise sentinel node identification with
more sensitive and informative ultrastaging molecular tech-
niques will likely revolutionize the way we stage lung cancer
and decide on appropriate postoperative treatment plans.
Currently, conflicting data exist to support the adminis-
tration of chemotherapy for localized completely resected
lung cancer, although clinical trials continue to investigate
this intervention. If improvements in systemic therapy are
forthcoming, more accurate or “ultrastaging” techniques
may assist in selecting patients at highest risk for recurrence
and perhaps most likely to benefit from additional therapies.
The current study by Nomori and colleagues9 is a wel-
come addition to the growing experience of the sentinel
node mapping technique. Their results confirm the promise
of this staging tool to assist in giving patients the most
precise information about their disease and aid in the iden-
tification of those most likely to benefit from future adjuvant
therapies. These findings await broader application in re-
sectable lung cancer to refine the sentinel node mapping
technique and patient selection criteria.
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